NFJ Investment Group LLC Sells 10,999 Shares of LivaNova PLC $LIVN

NFJ Investment Group LLC trimmed its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 21.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,170 shares of the company’s stock after selling 10,999 shares during the period. NFJ Investment Group LLC owned about 0.08% of LivaNova worth $2,533,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Hantz Financial Services Inc. raised its stake in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares during the period. State of Wyoming bought a new stake in LivaNova in the 2nd quarter valued at about $31,000. EverSource Wealth Advisors LLC raised its stake in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after acquiring an additional 639 shares during the period. Quarry LP bought a new stake in LivaNova in the 3rd quarter valued at about $36,000. Finally, Covestor Ltd raised its stake in LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after acquiring an additional 392 shares during the period. 97.64% of the stock is currently owned by institutional investors.

LivaNova Price Performance

LIVN stock opened at $79.39 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $4.36 billion, a PE ratio of 40.71 and a beta of 0.88. LivaNova PLC has a twelve month low of $41.01 and a twelve month high of $80.74. The stock has a 50-day simple moving average of $69.08 and a two-hundred day simple moving average of $65.81.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The business had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities analysts predict that LivaNova PLC will post 3.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on LIVN shares. Mizuho boosted their price objective on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Barclays boosted their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Robert W. Baird lowered their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Stifel Nicolaus set a $80.00 price objective on LivaNova in a research note on Wednesday, February 25th. Finally, Piper Sandler restated an “overweight” rating and issued a $85.00 price objective on shares of LivaNova in a research note on Thursday, February 19th. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $79.38.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director owned 7,228 shares of the company’s stock, valued at $547,521. The trade was a 19.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.35% of the stock is owned by insiders.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.